Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Voorraadrapport

Marktkapitalisatie: US$5.3b

Crinetics Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Crinetics Pharmaceuticals is R. Struthers, benoemd in Dec2008, heeft een ambtstermijn van 15.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.75M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.13% van de aandelen van het bedrijf, ter waarde $ 60.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 4.2 jaar.

Belangrijke informatie

R. Struthers

Algemeen directeur

US$5.7m

Totale compensatie

Percentage CEO-salaris10.7%
Dienstverband CEO15.9yrs
Eigendom CEO1.1%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur4.2yrs

Recente managementupdates

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Analyse CEO-vergoeding

Hoe is R. Struthers's beloning veranderd ten opzichte van Crinetics Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$278m

Jun 30 2024n/an/a

-US$259m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$38m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$3mUS$410k

-US$27m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$385kUS$350k

-US$9m

Compensatie versus markt: De totale vergoeding ($USD 5.75M ) R. } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.84M ).

Compensatie versus inkomsten: De vergoeding van R. is gestegen terwijl het bedrijf verliesgevend is.

CEO

R. Struthers (61 yo)

15.9yrs

Tenure

US$5,747,994

Compensatie

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
R. Struthers
Founder15.9yrsUS$5.75m1.13%
$ 60.0m
Stephen Betz
Founder & Chief Scientific Officer3.1yrsUS$2.50m0.022%
$ 1.2m
Marc J. Wilson
Chief Financial Officer6.8yrsUS$2.51m0.064%
$ 3.4m
Jeff Knight
Chief Operating Officer3.2yrsUS$2.36m0.0045%
$ 238.2k
Alan Krasner
Chief Endocrinologist6.4yrsUS$2.16m0.014%
$ 765.3k
Gayathri Diwakar
Head of Investor Relationsno datageen gegevensgeen gegevens
Garlan Adams
General Counsel & Corporate Secretary3.4yrsgeen gegevensgeen gegevens
Adriana Cabre
Chief Human Resources Officer4.5yrsgeen gegevensgeen gegevens
Kevin Capps
Head of Intellectual Propertyno datageen gegevensgeen gegevens
Chris Robillard
Chief Business Officer2.7yrsgeen gegevensgeen gegevens
Dana Pizzuti
Chief Medical & Development Officer2.2yrsUS$3.61m0.0024%
$ 125.4k
Robert Cuddihy
Senior Vice President of Medical Affairsless than a yeargeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CRNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
R. Struthers
Founder16yrsUS$5.75m1.13%
$ 60.0m
Wendell Wierenga
Independent Chairman of the Board9.1yrsUS$375.31k0.12%
$ 6.2m
Matthew Fust
Independent Director6.8yrsUS$348.56k0.021%
$ 1.1m
Camille Bedrosian
Independent Director4.2yrsUS$339.56k0.0067%
$ 352.5k
Beverly M. Biller
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Rogerio Vivaldi Coelho
Independent Director2.8yrsUS$338.56k0.012%
$ 646.7k
Weston Nichols
Independent Director6.8yrsUS$338.56k0.0067%
$ 352.5k
Stephanie Okey
Independent Director5.3yrsUS$342.31k0.0067%
$ 352.5k
Caren Deardorf
Independent Director2.7yrsUS$330.06k0.0067%
$ 352.5k
Martin Heinrich Reincke
Member of Scientific Advisory Board2.6yrsgeen gegevensgeen gegevens
John Newell-Price
Member of Scientific Advisory Board2.6yrsgeen gegevensgeen gegevens
William Young
Member of Scientific Advisory Board2.6yrsgeen gegevensgeen gegevens

4.2yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).